Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study-Reference-Cited by-同舟云学术

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Published:2018-02-02 Issue:8 Volume:32 Page:1799-1803
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Rule S^ORCID,Jurczak W,Jerkeman M,Rusconi C,Trneny M,Offner F,Caballero D,Joao C,Witzens-Harig M,Hess G,Bence-Bruckler I,Cho S-G^ORCID,Thieblemont C,Zhou W,Henninger T,Goldberg J,Vermeulen J,Dreyling M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0023-2.pdf

Reference10 articles.

1. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:512–8.

2. IMBRUVICA® [US prescribing information]. Sunnyvale, CA: Pharmacyclics, LLC; Horsham, PA: Janssen Biotech, Inc.; 2017.

3. Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.

4. Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62–iv71.

5. Dreyling M, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international randomised, open-label, phase 3 study. Lancet. 2016;387:770–8.

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions;Blood;2024-08-22

2. Infections in patients with mantle cell lymphoma;HemaSphere;2024-07

3. Molekular zielgerichtete Therapien – brauchen wir überhaupt noch Chemotherapie?;DMW - Deutsche Medizinische Wochenschrift;2024-05

4. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma;International Journal of Clinical Oncology;2023-12-29

5. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023;Journal of the National Comprehensive Cancer Network;2023-11